B. Riley Has Negative Outlook for Lam Research Q3 Earnings

Lam Research Co. (NASDAQ:LRCX) – Analysts at B. Riley dropped their Q3 2025 earnings per share estimates for Lam Research in a research note issued to investors on Wednesday, October 23rd. B. Riley analyst C. Ellis now forecasts that the semiconductor company will post earnings per share of $0.82 for the quarter, down from their prior estimate of $0.86. B. Riley has a “Buy” rating and a $105.00 price objective on the stock. The consensus estimate for Lam Research’s current full-year earnings is $3.23 per share. B. Riley also issued estimates for Lam Research’s Q4 2025 earnings at $0.88 EPS, FY2025 earnings at $3.39 EPS, Q1 2026 earnings at $0.99 EPS, Q2 2026 earnings at $1.07 EPS, Q3 2026 earnings at $1.02 EPS, Q4 2026 earnings at $1.08 EPS and FY2026 earnings at $4.16 EPS.

Lam Research (NASDAQ:LRCX) last announced its quarterly earnings data on Wednesday, October 23rd. The semiconductor company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.81 by $0.05. The firm had revenue of $4.17 billion during the quarter, compared to analyst estimates of $4.06 billion. Lam Research had a net margin of 25.68% and a return on equity of 48.71%. Lam Research’s revenue was up 19.7% on a year-over-year basis. During the same period last year, the firm posted $6.85 EPS.

A number of other equities analysts have also issued reports on the company. Morgan Stanley reduced their target price on Lam Research from $81.00 to $77.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Wells Fargo & Company decreased their target price on Lam Research from $88.00 to $85.00 and set an “equal weight” rating for the company in a report on Thursday, October 24th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $100.00 price target on shares of Lam Research in a report on Thursday, October 24th. Citigroup reduced their price target on shares of Lam Research from $99.00 to $89.30 and set a “buy” rating for the company in a research report on Monday, September 16th. Finally, TD Cowen upped their price objective on shares of Lam Research from $100.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Seven research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat, Lam Research has a consensus rating of “Moderate Buy” and a consensus target price of $97.03.

Lam Research Trading Up 3.8 %

NASDAQ LRCX opened at $78.31 on Monday. The stock has a market cap of $10.24 billion, a P/E ratio of 2.88, a P/E/G ratio of 1.89 and a beta of 1.47. The company has a current ratio of 2.97, a quick ratio of 2.00 and a debt-to-equity ratio of 0.52. Lam Research has a 12-month low of $57.44 and a 12-month high of $113.00. The company has a fifty day simple moving average of $78.79 and a two-hundred day simple moving average of $89.37.

Lam Research Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, October 1st. Stockholders of record on Tuesday, September 17th were given a dividend of $0.23 per share. This represents a $0.92 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date of this dividend was Tuesday, September 17th. Lam Research’s dividend payout ratio (DPR) is presently 3.38%.

Insider Buying and Selling

In other news, CAO Christina Correia sold 647 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $817.51, for a total transaction of $528,928.97. Following the completion of the transaction, the chief accounting officer now directly owns 4,267 shares of the company’s stock, valued at $3,488,315.17. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 0.32% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Lam Research

Several institutional investors and hedge funds have recently added to or reduced their stakes in LRCX. Van ECK Associates Corp grew its position in shares of Lam Research by 1,394.7% in the third quarter. Van ECK Associates Corp now owns 16,081,071 shares of the semiconductor company’s stock valued at $13,123,440,000 after purchasing an additional 15,005,178 shares during the period. Vanguard Group Inc. boosted its holdings in Lam Research by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 11,856,661 shares of the semiconductor company’s stock worth $11,519,576,000 after buying an additional 144,914 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Lam Research by 5.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,959,151 shares of the semiconductor company’s stock worth $2,875,023,000 after buying an additional 142,903 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Lam Research by 7.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 1,254,188 shares of the semiconductor company’s stock valued at $1,335,522,000 after acquiring an additional 89,470 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Lam Research by 4.3% in the second quarter. Dimensional Fund Advisors LP now owns 614,205 shares of the semiconductor company’s stock valued at $654,009,000 after acquiring an additional 25,362 shares in the last quarter. Hedge funds and other institutional investors own 84.61% of the company’s stock.

Lam Research Company Profile

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.